Radiopharm Theranostics Limited - American Depositary Shares (RADX) closed at $0.69 on November 18, 2026, up 2.1% from the previous close, on volume of 15,176 shares (30-day average 49,671).
Data as of November 18, 2026.
Radiopharm Presents Interim RAD101 Phase 2b Brain Metastases Data
TipRanks (Mon, 16-Nov 8:39 AM ET)
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
Globe Newswire (Mon, 9-Nov 11:56 AM ET)
Globe Newswire (Thu, 5-Nov 8:35 AM ET)
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Radiopharm Theranostics Reports Business Update
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Globe Newswire (Mon, 14-Sep 8:00 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Globe Newswire (Wed, 26-Aug 7:00 AM ET)
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Australia and the United States, with maximum revenue from the United States.
Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.
As of November 19, 2026, RADX stock price declined to $0.67 with 26,919 million shares trading.
RADX has a beta of 0.60, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.01 to the broad based SPY ETF.
RADX has a market cap of $10.52 million. This is considered a Sub-Micro Cap stock.
RADX has underperformed the market in the last year with a price return of -84.4% while the SPY ETF gained +9.8%. RADX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.4% and -22.9%, respectively, while the SPY returned -6.3% and -6.5%, respectively.
RADX support price is $.61 and resistance is $.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.